Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Cash (2016 - 2025)

Historic Change in Cash for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$625000.0.

  • Harvard Bioscience's Change in Cash fell 21996.16% to -$625000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 39156.94%. This contributed to the annual value of -$175000.0 for FY2024, which is 2222.22% up from last year.
  • Latest data reveals that Harvard Bioscience reported Change in Cash of -$625000.0 as of Q3 2025, which was down 21996.16% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Change in Cash registered a high of $2.3 million during Q4 2021, and its lowest value of -$2.5 million during Q1 2021.
  • Over the past 5 years, Harvard Bioscience's median Change in Cash value was -$207000.0 (recorded in 2024), while the average stood at -$78947.4.
  • As far as peak fluctuations go, Harvard Bioscience's Change in Cash plummeted by 48926.55% in 2021, and later soared by 523571.43% in 2025.
  • Over the past 5 years, Harvard Bioscience's Change in Cash (Quarter) stood at $2.3 million in 2021, then crashed by 127.98% to -$636000.0 in 2022, then crashed by 66.19% to -$1.1 million in 2023, then surged by 56.39% to -$461000.0 in 2024, then crashed by 35.57% to -$625000.0 in 2025.
  • Its last three reported values are -$625000.0 in Q3 2025, $1.9 million for Q2 2025, and $1.4 million during Q1 2025.